Cyclic adenosine monophosphate boronic acid complex and preparation method thereof, as well as antitumor drug and boron agent for neutron capture therapy

Abstract

The invention discloses a cyclic adenosine monophosphate boric acid complex, a preparation method thereof, an anti-tumor drug and a neutron capture therapy boron agent. The cyclic adenosine monophosphate boric acid complex serves as a boron-containing compound, a boron-containing epidermal growth factor receptor inhibitor and a boron-containing nucleoside epidermal growth factor receptor inhibitor, cancer cells absorb the boron agent, propagation of the cancer cells needs a lot of nucleosides, so that the drug is enriched to sensitive targets such as cancer cell membranes, cancer cells are killed by the aid of neutron capture specificity, drug selectivity is widened, so that the killed efficiency of the cancer cells is greatly improved, and the cyclic adenosine monophosphate boric acid complex solves the problems that most boron agents in current neutron capture therapy only have single function, only the one-sided effect of selectively absorbing neutron energy to kill tumors is improved in neutron capture therapy, the killed efficiency of the cancer cells is low, and selectivity is poor.

Description

technical field [0001] The invention relates to the technical field of antitumor drugs, in particular to a cyclic adenosine monophosphate boric acid complex and a preparation method thereof, as well as antitumor drugs and boron agents for neutron capture therapy. Background technique [0002] With the continuous development of medical technology, the technology of radiation killing tumors has also changed from non-selective X, gamma radiation (common medical accelerator) to proton and heavy ion radiation therapy with certain longitudinal energy selection (Borrag peak). especially use 10 B molecules capture epithermal low-energy neutrons (1eV ~ 10keV) to generate nuclear reactions (~ 3MeV) in tumor cells. Boron neutron capture therapy (BNCT), which has a higher level of selective tumor killing, is the most recently studied in the world. hotspot. [0003] BNCT is the boron ( 10 B) The compound carrier is injected into the human body, selectively enriched in tumor cells, and...

AI Technical Summary

Problems solved by technology

[0005] The main purpose of the present invention is to provide a kind of cyclic adenosine monophosphate boronic acid complex and preparation method, and the boron agent of antineoplastic drug and BNCT, aim to solve existing boron agent major part for present BNCT only has single The function is only to improve the unilateral effect of selectively absorbing neutron energy in its BNCT to kill tumors. The tumor cell killing efficiency is low and the selectivity is poor.

Images